Breaking Age Barriers: The Benefits of CAR T-Cell Therapies in Treating Large B-Cell Lymphoma in Older Patients
The management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in older patients is challenging due to increased morbidity, toxicity and reduced effectiveness of therapy in this vulnerable and difficult-to-treat population. Chimeric antigen receptor (CAR) T-cell therapies have become a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2023.18.132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in older patients is challenging due to increased morbidity, toxicity and reduced effectiveness of therapy in this vulnerable and difficult-to-treat population. Chimeric antigen receptor (CAR) T-cell therapies have become a breakthrough in the treatment of lymphoid malignancies, including DLBCL. Although CAR T-cell immunotherapy may significantly improve clinical outcomes, its toxicity raised concerns as to whether this therapeutic approach is beneficial for geriatric patients. The current paper summarizes the data from recent studies that evaluated the efficacy and safety of CAR T-cell products in older patients with DLBCL.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Dr Wiebke Rösler (University Hospital Zurich, Zurich, Switzerland)
Three anonymous peer reviewer.
Submitted on November 16, 2023; accepted on December 19, 2023; published online on December 22, 2023. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |